Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Velcade Prescribers for CML (US)(?)

Council Members in this Study Group: 79

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Eric Jacobsen, MD
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School

Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at the Dana Farber Cancer Institute in Boston, MA. His clinical focus is on lymphoma, and he is very involved in Phase II/III clinical trials for new compounds, as well as stem cell transplantation.

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD
Medical Director of Hematology
Big Sky Oncology

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...

Michael Grossbard, MD
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

Donald Tsai, MD PhD
Assistant Professor of Medicine
University of Pennsylvania Cancer Center

Donald Tsai, MD, PhD, is Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....

View all Leading Experts in this Study Group

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Avastin Raises Risk of Clots: New News? | 12-01-2008
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.

It's always what's relative and seldom absolute | 11-26-2008
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Satistics are usually used to reveal dramatic differences Patients often misinterpret relative differences for absolute ones patients are willing to do a lot more to get any benefit in cancer outcome

The rash and EGFR response can be helpful | 11-19-2008
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Many studies support EGFR response correlates with rash Many attempts to actually increase the incidence of rash Most patients will use the EGFR treatments despite the rash

When being selective, targeted therapy will work | 11-13-2008
Analysis of: Tarceva successful as maintenance therapy | www.fiercebiotech.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Saturn trial attempted to focus on EGFR reative patients Saturn was positive as a maintenance therapy, while concurrent was not

Big Pharma will continue to thrive in new administration, but not insurnace companies | 11-10-2008
Author: GLG Expert Contributor

President elect Obama will try , most probably unsuccessfully, to take on insurance companies in orfder to fulfill his election promises of "close to universal" health care. Generics will thrive, but Big Phrama , especially those with innovative products and biotech companies will continue to pr...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Director

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-04T21:45:18.380